IDH2 and acute myeloid leukemia: Additionally, there are ongoing studies investigating the use of enasidenib (100 mg/day) (or ivosidenib, see above) in combination with induction or consolidation therapies (daunorubicin 60 mg/m2/day or idarubicin 12 mg/m2/day for 3 days with cytarabine 200 mg/m2/day for 7 days) (NCT02632708) and the combinational use of enasidenib (100 mg/day) with azacitidine (75 mg/m2/day) in newly diagnosed IDH2-mutated AML patients (NCT02677922).